AstraZeneca: AIRSUPRA (PT027) Approved In The US For Asthma
January 12, 2023
January 12, 2023
WILMINGTON, Delaware, Jan. 12 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Jan. 11, 2023:
AIRSUPRATM (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
The approval by the Food and Drug Administration (FDA) was based on results from the MANDALA and D . . .
AIRSUPRATM (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
The approval by the Food and Drug Administration (FDA) was based on results from the MANDALA and D . . .